An Independently Validated Survival Nomogram for Lower-grade Glioma

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2019 Oct 18

PMID 31621885

Citations 97

Authors

Haley Gittleman

Andrew E Sloan

Jill S Barnholtz-Sloan

Affiliations

Soon will be listed here.

Abstract

Background: Gliomas are the most common primary malignant brain tumor. Diffuse low-grade and intermediate-grade gliomas, which together compose the lower-grade gliomas (LGGs; World Health Organization [WHO] grades II and III), present a therapeutic challenge to physicians due to the heterogeneity of their clinical behavior. Nomograms are useful tools for individualized estimation of survival. This study aimed to develop and independently validate a survival nomogram for patients with newly diagnosed LGG.

Methods: Data were obtained for newly diagnosed LGG patients from The Cancer Genome Atlas (TCGA) and the Ohio Brain Tumor Study (OBTS) with the following variables: tumor grade (II or III), age at diagnosis, sex, Karnofsky performance status (KPS), and molecular subtype (IDH mutant with 1p/19q codeletion [IDHmut-codel], IDH mutant without 1p/19q codeletion, and IDH wild-type). Survival was assessed using Cox proportional hazards regression, random survival forests, and recursive partitioning analysis, with adjustment for known prognostic factors. The models were developed using TCGA data and independently validated using the OBTS data. Models were internally validated using 10-fold cross-validation and externally validated with calibration curves.

Results: A final nomogram was validated for newly diagnosed LGG. Factors that increased the probability of survival included grade II tumor, younger age at diagnosis, having a high KPS, and the IDHmut-codel molecular subtype.

Conclusions: A nomogram that calculates individualized survival probabilities for patients with newly diagnosed LGG could be useful to health care providers for counseling patients regarding treatment decisions and optimizing therapeutic approaches. Free online software for implementing this nomogram is provided: https://hgittleman.shinyapps.io/LGG_Nomogram_H_Gittleman/.

Key Points: 1. A survival nomogram for lower-grade glioma patients has been developed and externally validated.2. Free online software for implementing this nomogram is provided allowing for ease of use by practicing health care providers.

Citing Articles

Integration of histone modification-based risk signature with drug sensitivity analysis reveals novel therapeutic strategies for lower-grade glioma.

Wang J, Yan S Front Pharmacol. 2025; 15:1523779.

PMID: 39872055 PMC: 11770009. DOI: 10.3389/fphar.2024.1523779.

Computed Tomography-Image-Based Glioma Grading Using Radiomics and Machine Learning: A Proof-of-Principle Study.

Bilgin M, Bilgin S, Akkurt B, Heindel W, Mannil M, Musigmann M Cancers (Basel). 2025; 17(2).

PMID: 39858104 PMC: 11763433. DOI: 10.3390/cancers17020322.

Multi-center real-world data-driven web calculator for predicting outcomes in IDH-mutant gliomas: Integrating molecular subtypes and treatment modalities.

Xu H, Liu B, Wang Y, Zhu R, Jiang S, Soliman L Neurooncol Adv. 2025; 7(1):vdae221.

PMID: 39844832 PMC: 11751580. DOI: 10.1093/noajnl/vdae221.

Predictive and prognostic nomogram models for liver metastasis in colorectal neuroendocrine neoplasms: a large population study.

Lei X, Su Y, Lei R, Zhang D, Liu Z, Li X Front Endocrinol (Lausanne). 2025; 15():1488733.

PMID: 39839478 PMC: 11746099. DOI: 10.3389/fendo.2024.1488733.

Increased expression of () predicts poor prognosis and is correlated with immune-cell infiltration in glioma.

Shi L, Chen H, Chen J, Palmer J, Wang L, Sheng L Transl Cancer Res. 2024; 13(11):6298-6314.

PMID: 39697738 PMC: 11651804. DOI: 10.21037/tcr-24-1982.

References

Yang T, Mao P, Chen X, Niu X, Xu G, Bai X . Inflammatory biomarkers in prognostic analysis for patients with glioma and the establishment of a nomogram. Oncol Lett. 2019; 17(2):2516-2522. PMC: 6351731. DOI: 10.3892/ol.2018.9870. View

Shete S, Hosking F, Robertson L, Dobbins S, Sanson M, Malmer B . Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009; 41(8):899-904. PMC: 4501476. DOI: 10.1038/ng.407. View

Harrell Jr F, Lee K, Mark D . Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15(4):361-87. DOI: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4. View

Eckel-Passow J, Lachance D, Molinaro A, Walsh K, Decker P, Sicotte H . Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015; 372(26):2499-508. PMC: 4489704. DOI: 10.1056/NEJMoa1407279. View

Gorovets D, Kannan K, Shen R, Kastenhuber E, Islamdoust N, Campos C . IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res. 2012; 18(9):2490-501. DOI: 10.1158/1078-0432.CCR-11-2977. View

Ostrom Q, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan J . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol. 2018; 20(suppl_4):iv1-iv86. PMC: 6129949. DOI: 10.1093/neuonc/noy131. View

Ceccarelli M, Barthel F, Malta T, Sabedot T, Salama S, Murray B . Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016; 164(3):550-63. PMC: 4754110. DOI: 10.1016/j.cell.2015.12.028. View

Stupp R, Brada M, van den Bent M, Tonn J, Pentheroudakis G . High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii93-101. DOI: 10.1093/annonc/mdu050. View

Liu J, Lichtenberg T, Hoadley K, Poisson L, Lazar A, Cherniack A . An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018; 173(2):400-416.e11. PMC: 6066282. DOI: 10.1016/j.cell.2018.02.052. View

10.

Cavaliere R, Lopes M, Schiff D . Low-grade gliomas: an update on pathology and therapy. Lancet Neurol. 2005; 4(11):760-70. DOI: 10.1016/S1474-4422(05)70222-2. View

11.

Chen H, Judkins J, Thomas C, Wu M, Khoury L, Benjamin C . Mutant IDH1 and seizures in patients with glioma. Neurology. 2017; 88(19):1805-1813. PMC: 5419985. DOI: 10.1212/WNL.0000000000003911. View

12.

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

13.

Brat D, Verhaak R, Aldape K, Yung W, Salama S, Cooper L . Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015; 372(26):2481-98. PMC: 4530011. DOI: 10.1056/NEJMoa1402121. View

14.

Pouratian N, Schiff D . Management of low-grade glioma. Curr Neurol Neurosci Rep. 2010; 10(3):224-31. PMC: 2857752. DOI: 10.1007/s11910-010-0105-7. View

15.

Feyissa A, Worrell G, Tatum W, Chaichana K, Jentoft M, Guerrero Cazares H . Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control. Seizure. 2019; 69:283-289. DOI: 10.1016/j.seizure.2019.05.018. View

16.

Gorlia T, van den Bent M, Hegi M, Mirimanoff R, Weller M, Cairncross J . Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2007; 9(1):29-38. DOI: 10.1016/S1470-2045(07)70384-4. View

17.

Wang Y, Xin S, Zhang K, Shi R, Bao X . Low GAS5 Levels as a Predictor of Poor Survival in Patients with Lower-Grade Gliomas. J Oncol. 2019; 2019:1785042. PMC: 6377997. DOI: 10.1155/2019/1785042. View

18.

Gittleman H, Lim D, Kattan M, Chakravarti A, Gilbert M, Lassman A . An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro Oncol. 2017; 19(5):669-677. PMC: 5464437. DOI: 10.1093/neuonc/now208. View

19.

Wang Z, Chen H . Relationship between IDH1 mutation and preoperative seizure in low-grade gliomas: A meta-analysis. Clin Neurol Neurosurg. 2016; 148:79-84. DOI: 10.1016/j.clineuro.2016.07.003. View

20.

Gorlia T, Wu W, Wang M, Baumert B, Mehta M, Buckner J . New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro Oncol. 2013; 15(11):1568-79. PMC: 3813419. DOI: 10.1093/neuonc/not117. View